Year: 2023

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

Written by Customer Service on November 7, 2023. Posted in Public Companies.

BERKELEY, Calif. and MAINZ, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that VP Commercial Operations, Tarrin Khairi-Taraki, will attend MEDICA by invitation of the Rhineland-Pfalz government. Held in Dusseldorf, Germany from 13-16 November, MEDICA draws over 4,500 exhibitors from 66 countries and more than 81,000 visitors from all over the world, making it one of the largest medical B2B trade fairs in the world. Global healthcare experts, commercial decision makers, politicians and policy makers take part in an extensive programme of first-class forums, conferences and special shows at the event. Mr. Khairi-Taraki will be showcasing ColoAlert® the Company’s flagship...

Melco Announces Unaudited Third Quarter 2023 Earnings

Written by Customer Service on November 7, 2023. Posted in Public Companies.

MACAU, Nov. 07, 2023 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner, and operator of integrated resort facilities in Asia and Europe, today reported its unaudited financial results for the third quarter of 2023. Total operating revenues for the third quarter of 2023 were US$1.02 billion, representing an increase of approximately 321% from US$241.8 million for the comparable period in 2022. The increase in total operating revenues was primarily attributable to the improved performance in all gaming segments and non-gaming operations following the relaxation of COVID-19 related restrictions in Macau in January 2023 and the opening of Studio City Phase 2. Operating income for the third quarter of 2023 was US$94.7 million, compared with operating loss of US$198.5...

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Written by Customer Service on November 7, 2023. Posted in Public Companies.

Company on track to report top line data milestone in 1Q 2024 A total of 210 participants have been recruited Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvementMADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder (BPD). PORTICO (EudraCT No.: 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) is a global double-blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial evaluating the efficacy and safety of vafidemstat...

Terra Balcanica Drills 1168 g/t AgEq Over 1.35 m At Cumavici Ridge And Confirms New Mineralization Over 600 m Northwest

Written by Customer Service on November 7, 2023. Posted in Public Companies.

News Release Video: Terra Balcanica produced a technical webinar to explain the drill results. Vancouver, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) is pleased to announce initial assay results from the Phase II drill campaign confirming continuation of the high-grade Cumavici Ridge epithermal vein within its principal Viogor-Zanik project in Bosnia and Herzegovina. HighlightsDrillhole CMV23004 intersected 1,168 g/t AgEq (including 452 g/t Ag, 3.49 g/t Au, and 3.36% Zn) over 1.35 m from 36.2 m downhole (Table 1);Successful results from CMV23004 add approximately 50 m strike length SE of previously reported CMVDD002 which returned 816.1 g/t AgEq over 2 m (see company news release dated 22nd October 2022) with mineralization remaining open...

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

Written by Customer Service on November 7, 2023. Posted in Public Companies.

PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced that the Company will release financial results for the third quarter of 2023 on Tuesday, November 14, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update. Tuesday, November 14, 2023, 8:00 AM ET Domestic: 877-407-3088International: 201-389-0927 Conference ID: 13741454 Webcast: PDS Biotech Earnings Webcast After the live webcast, the event will be archived on PDS Biotech’s website for six months. About...

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

Written by Customer Service on November 7, 2023. Posted in Public Companies.

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:Jefferies London Healthcare Conference on Tuesday, November 14th at 11:00AM GMT (6:00AM ET). 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28th at 2:00PM ET.Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events. About Pacira Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address...

Hampton Financial Corporation to Acquire Oxygen Working Capital Corp.

Written by Customer Service on November 7, 2023. Posted in Mergers And Acquisitions.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 07, 2023 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Company”, TSXV:HFC) today announced that it has entered into a non-binding letter of intent, dated as of October 31, 2023, to acquire Oxygen Working Capital Corp.(“OCC”), representing its first foray into the Commercial Lending sector. OCC is a specialized lender focused on the Commercial Factoring business with clients across Canada and prospects for continued growth. The transaction will be subject to various regulatory approvals and certain commercial conditions including remaining due diligence and the approval of Hampton’s Board. In the transaction’s current format Hampton will acquire from the limited partners of Terra Cotta Strategic Capital –...

Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended September 30, 2023 and Declaration of Distributions on Common Stock for the Months Ending January 31, February 29, and March 31, 2024

Written by Customer Service on November 7, 2023. Posted in Earnings Releases And Operating Results.

GREENWICH, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQL) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended September 30, 2023.On November 2, 2023, our Board of Directors declared the following distributions on our common stock:Month Ending Record Date Payment Date Amount Per ShareJanuary 31, 2024 January 17, 2024 January 31, 2024 $0.035February 29, 2024 February 15, 2024 February 29, 2024 $0.035March 31, 2024 March 15, 2024 March 29, 2024 $0.035Net asset value (“NAV”) per share as of September 30, 2023 stood at $2.78, compared with a NAV per share on June 30, 2023 of $2.88.Net investment income (“NII”) was approximately $6.4 million, or $0.11 per...

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on November 7, 2023. Posted in Earnings Releases And Operating Results.

The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma An initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma Initial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancers A recap of interim data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancer recently presented at SITC 2023WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial...

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Written by Customer Service on November 7, 2023. Posted in Earnings Releases And Operating Results.

Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension trial Reported statistically significant long-term survival benefit of 70% decreased risk of death associated with CNM-Au8 treatment in the HEALEY ALS Platform Trial compared to PRO-ACT historical controls Awarded $45.1 million NINDS grant to support research and expanded access of CNM-Au8 in people living with ALS Announced peer-reviewed publication characterizing CNM-Au8 neuroprotective mechanism of action in the nanotechnology-focused journal, Small Cash and cash equivalents of $42.1 million as of September 30, 2023, which includes gross proceeds of $40 million from a public offering in June and that may provide additional capital of up to...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals